

ASHBi SEMINAR

2024

11.05 THU

17:00-18:30

Registration



Venue

Conference Room ◀◀◀ Onsite Only

B1F, Faculty of Medicine Bldg. B

Lecturer

Corine Bertolotto Ph.D.
Research Director, INSERM

Robert Ballotti Ph.D.
Research Director, INSERM

“Understanding the molecular mechanisms involved in uveal melanoma progression to reveal new actionable vulnerabilities”

Lecturer: **Corine Bertolotto** Ph.D.



Uveal melanoma (UM) which develops from uveal melanocyte is the main primary intraocular malignancy in adults. UM is genetically and biologically distinct from cutaneous melanoma. UM metastases are highly refractory to existing treatments, most patients die within a year of diagnosis. It is therefore urgent to continue understanding the molecular mechanisms involved in UM progression to find effective treatments. Our work has identified novel candidates that can be exploited for improving UM treatment and patient's survival.



“Identifying the Epigenetic Players Involved in Melanoma Resistance to Targeted Therapies and to the Immune System”

Lecturer: **Robert Ballotti** Ph.D.

Targeted-(TT) and immuno-therapies (IT) has significantly improved survival of patients with metastatic melanoma. However, almost 50% of patients relapse due to resistance to treatments. The main challenge today is to decipher the mechanisms of resistance and identify new therapeutic targets.

Our recent data identified epigenetic players involved in the acquisition of TT resistance and in the alteration of the immune response in melanoma cells. These results lay the foundations for new therapeutic strategies targeting epigenetic alterations to overcome resistance.

Hosted by Institute for the Advanced Study of Human Biology (WPI-ASHBi)

Contact: Prof. Sungrim Seirin-Lee [ASHBi, Kyoto University] | lee.seirin.2c@kyoto-u.ac.jp

Assisant Prof. Akinori Kawakami [Dermatology, Graduate School of Medicine, Kyoto University]
| kawakamia@kuhp.kyoto-u.ac.jp

